StockMarketWire.com - Omega Diagnostics said its FY results will be in line with market expectations. Revenues for the year are seen at GBP12.7m and adjusted profit before tax will be in the range of GBP1.2m to GBP1.3m.

Revenue of GBP12.7m would be 6% ahead of last year in constant currency terms and 5% ahead of last year's result (GBP12.11m) on an actual basis.

CEO Andrew Shepherd commented:

"It is pleasing to see continued growth in the Food Intolerance business and also to reach the launch stage of the new Allersys allergy tests after a great amount of effort by the R&D team.

"While there are still challenges ahead, we remain confident that we will continue to see positive progress with the Visitect CD4 test development and together with the growth strategy as outlined we remain optimistic for a bright future for the Company."






Story provided by StockMarketWire.com